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Sprague-Dawley ratsObjective: The purpose of this research was to investigate sub-chronic toxicity in animal model.
Methods: A detailed study was done on the physical, hematological, biochemical and hormonal parame-
ters of both male and female Sprague-Dawley rats after 28 days administration of naproxen and its metal
complexes.
Results: There were no significant changes found in physical parameters on observation for both male
and female rats without some minor differences. However, Naproxen metal complexes showed compar-
atively lower side effects than naproxen. Hematological report suggested that naproxen was in process of
initiating inflammation which was justified by decreasing the mean value hemoglobin and hematocrit
level and increasing the white blood cells level. There were no significant changes in biochemical param-
eters, however, the mean value of blood glucose level and cholesterol seemed to be higher and triglyc-
eride was lower. Thyroid hormone levels were found lower, that was another indication inflammatory
process. However, this might have the ability to lower the insulin secretion resulting in increasing blood
glucose level.
Conclusion: In the present investigation, there were no significant alterations in histopathological studies
and physical parameters though some signs of abnormalities had been found but hematological and hor-
monal data did not suggest any inflammatory or toxicological activity. However, we observed that
naproxen showed more side effects than metal complexes which indicated that carboxylic group
(ACOOH) of naproxen may be responsible for showing those most of the side effects.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non steroidal anti-inflammatory drugs (NSAIDs) are one of the
most widely utilized classes of drugs due to their potent anti-
inflammatory, analgesic, and anti-pyretic properties in the world.1
The treatment of inflammation and pain is an important area of
therapeutics. In the last decade, nonsteroidal anti-inflammatory
drugs (NSAIDs) like naproxen have played a central role in these
indications and they are currently considered as the first choice,
being one of the most widely prescribed drugs.2,3 Naproxen is a
non steroidal anti-inflammatory, analgesic drug which is exten-
sively used in the clinical treatment of acute and chronic pain
and arthritis.4 They inhibit both cyclooxygenase-1 (COX-1) and
cyclooxygenase-2 (COX-2) isoenzymes involved in the synthesis
of prostaglandins.5 Prostaglandins are chemicals produced by the
cells of the body promoting inflammation, pain and fever; support-ing the blood clotting function of platelets and protecting stomach
from the damaging effects of acid.6,7 Cyclooxygenase-1 is constitu-
tively expressed and generates prostanoids involved in the mainte-
nance of the integrity of gastrointestinal mucosa and platelet
aggregation8 whereas at sites of inflammation, cyclooxygenase-2
is induced to generate prostaglandins that mediate inflammation
and pain.9 They are highly effective for their anti-inflammatory
and analgesic properties in treating different level of pains, such
as osteoarthritis and rheumatoid arthritis10 and may reduce the
risk of colon cancer and probably various types of gastrointestinal
(GI)-related cancers.11 Despite all of those successes, many studies
reveal that gastric or duodenal ulcers develop in 15–30 percent of
patients who regularly take NSAIDs12 and more than 100,000
patients are hospitalized and 16,500 die every year in America as
a result of NSAID induced gastrointestinal events.13,14
As there is no information available on the sub-chronic toxico-
logical effects of metal complexes of naproxen in the animal model
compared to naproxen, we have motivated to study metal binding
properties of naproxen with different transition metal ions
with the aims of investigating their physical, hematological,
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toxicity in animal model. In this paper, we report the synthesis of
some organ metallic compounds of naproxen and their ability to
reduce gastrointestinal toxicity.2. Materials and methods
2.1. General procedure for synthesis of transition metal complexes of
naproxen
All synthetic procedures were described in details by Hasan
et al.152.2. Method consideration, dose selection and route of administration
The sub-chronic model was used to evaluate NSAID induced
pathological state in young, healthy rat model to see overall effect
on the health of the animals over the 28 days dosing period. The
sub-chronic model allows one to assess the test NSAID’s toxicity
with regard to GI bleeding (hemoglobin, hematocrit reduction),
the development of intestinal perforation and adhesions.16 The
dose of naproxen employed in the rat studies was equivalent to
10 mg/kg body weight. This dose was selected because it produced
significant and comparable activity in reducing paw swelling in
rats with adjuvant arthritis and also producing several side effects
including ulceration.17 Using this dose, other naproxen metal com-
plexes are also administered at a dose of 10 mg/kg and test sam-
ples were orally administered twice daily for 18 days.182.3. Experimental design
All experimental animals (Supplementary Sections 1.1 and 1.2)
were randomly selected and divided into seven groups in Table 1.2.4. Preparation of test samples
The calculated amount of the test samples were measured and
normal saline was added with 1–2 drops of a suspending agent. To
stabilize the suspension, it was stirred well by vortex mixture.
Finally the volume was adjusted up to such so as to have final vol-
ume with concentration vol-dose/group/2 administrations per
day.182.5. Sacrificing of the animals and methods of observation and
examination
At the end of treatment period (28 days), the animals were sac-
rificed, physical observation was performed and blood samples and
organs were collected for further experiments (Supplementary
Sections 1.3, 1.4 and 1.5).Table 1
Experimental design of naproxen metal complexes.
Groups Test samples No of animals
Group I Control 8
Group II Naproxen 8
Group III Naproxen copper complex 8
Group IV Naproxen cobalt complex 8
Group V Naproxen iron complex 8
Group VI Naproxen silver complex 8
Group VII Naproxen zinc complex 82.6. Histopathologic studies
2.6.1. Microscopic evaluation of histopathological study
The stomach was opened along with greater curvature, rinsed
with saline to remove gastric contents and blood clots using wash-
out technique19,20 and examined by a 5 magnifying lens to assess
the formation of ulcers. The stomach was removed and the number
of ulcers was counted.
2.6.2. Measurement of Ulcer score
Ulcer index was measured by using following formula.19 Ulcer
scoring was described in Table 2.
UI ¼ UNþ USþ UP 101
UI = Ulcer Index.
UN = Average number of ulcers per animal.
US = Average number of severity score.
UP = Ulcer probability (incidence%) for each group.
Percentage inhibition of ulceration was calculated as below:
% Inhibition of Ulceration ¼ ðUlcer indexStandard  Ulcer indexTest compoundÞ  100ðUlcer indexStandardÞ2.7. Statistical analysis
All the grouped data were statistically evaluated with SPSS ver-
sion 17 software. All the results were expressed as Mean ± SEM
(Standard Error of Mean) values for seven animals in each group.
Means were compared by two tailed independent sample t-test.
Probability (p) value of 0.05 or less (p < 0.05) was considered as
significant.
3. Results
3.1. Characterization of metal complexes of naproxen
Physical, analytical and thermal properties, NMR spectra, FTIR
spectra, scanning electron microscopy and HPLC study of naproxen
metal complexes were described by Hasan et al.15
3.2. Toxicological evaluation
3.2.1. Physical parameters
No significant changes were observed in both male and female
rats without some minor alterations within any sample groups
throughout the dosing period. No mortality was observed in all
groups of both male and female rats during the experiment (see
Fig. 1).
3.2.2. Weight variation of rats during the study period
In an attempt to observe any change in the body weight of the
tested animals induced by naproxen and its metal complexes, theTable 2
The number of ulcers was counted. Ulcer scoring was under-
taken21 as following manner.
Ulcer score Descriptive/observation
0 No ulcer/normal colored stomach
0.5 Red coloration




Fig. 1. Microscopic evaluation of ulceration of (a) control, (b) naproxen, (c) naproxen copper complex, (d) naproxen cobalt complex, (e) naproxen iron complex, (f) naproxen
silver complex, (g) naproxen zinc complex of the rat groups.
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Table 3
Hematological parameter changes of male rats during treatment of test compounds.
Parameters Control Standard (Naproxen) Nap-Cu Nap-Co Nap-Fe Nap-Ag Nap-Zn
WBC (109/L) 4.9 ± 0.36 7.44 ± 0.31* 4.9 ± 0.84 5.44 ± 0.61 6.72 ± 0.81 5.6 ± 0.49 5.97 ± 0.57
RBC (1012/L) 5.66 ± 0.17 4.72 ± 0.32* 5.98 ± 0.23 6.71 ± 0.22 5.88 ± 0.44 5.51 ± 0.21 5.67 ± 0.46
Platelets (1011/L) 5.88 ± 0.11 6.79 ± 0.61 5.01 ± 0.92 5.11 ± 0.11 5.32 ± 0.20 4.97 ± 0.66 5.1 ± 0.26
Neutrophils (109/L) 0.84 ± 0.07 1.57 ± 0.23*** 0.95 ± 0.08 1.22 ± 0.33 1.11 ± 0.02 0.98 ± 0.07 1.04 ± 0.06
Lymphocytes (109/L) 3.92 ± 0.76 5.66 ± 0.27* 4.78 ± 0.22 4.91 ± 0.44 4.88 ± 0.18 4.55 ± 0.12 4.78 ± 0.39
Monocytes (109/L) 0.05 ± 0.007 0.14 ± 0.02* 0.1 ± 0.02 0.1 ± 0.02 0.12 ± 0.01 0.07 ± 0.02 0.07 ± 0.02
Hemoglobin (gm/dL) 11.71 ± 0.71 9.11 ± 0.80** 11.01 ± 0.34 11.19 ± 0.20 10.61 ± 0.33 10.64 ± 0.17 10.88 ± 0.22
Hematocrit (HCT) (%) 32.62 ± 1.4 25.96 ± 1.2** 32.88 ± 0.51 30.91 ± 0.58 29.72 ± 1.4 30.89 ± 0.51 31.03 ± 0.96
MCV (fL) 54.92 ± 1.7 54.64 ± 0.65 53.07 ± 0.71 53.01 ± 0.70 53.98 ± 1.4 53.94 ± 0.91 52.65 ± 0.71
MCH (pg) 19.98 ± 0.63 19.76 ± 0.31 18.01 ± 0.67 18.11 ± 0.06 19.13 ± 0.45 19.6 ± 0.34 18.2 ± 0.35
MCHC (gm/dL) 34.44 ± 0.31 33.96 ± 0.12 34.02 ± 0.09 34.63 ± 0.11 34.15 ± 0.23 34.01 ± 0.11 34.38 ± 0.19
RDW (%) 18.33 ± 2.7 18.44 ± 0.28 14.92 ± 0.48 15.07 ± 0.61 16.67 ± 1.4 16.12 ± 0.56 16.01 ± 0.31
MPV (fL) 4.11 ± 0.07 4.19 ± 0.07 4.11 ± 0.09 4.21 ± 0.11 4.19 ± 0.04 4.11 ± 0.07 4.31 ± 0.08
PDW (10 GSD) 16.27 ± 0.11 16.22 ± 0.08 16.33 ± 0.16 16.84 ± 0.27 16.21 ± 0.11 16.5 ± 0.17 16.51 ± 0.19
ESR (mm in 1st hour) 2.47 ± 0.27 2.34 ± 0.21 2.11 ± 0.11 2.21 ± 0.12 2.12 ± 0.11 2.1 ± 0.01 2.67 ± 0.21
Bleeding time (sec) 47.11 ± 3.7 44.11 ± 3.1 41.11 ± 2.1 47.11 ± 3.7 41.34 ± 3.1 41.47 ± 3.1 39.68 ± 3.7
Clotting time (min) 3.68 ± 0.07 3.74 ± 0.11 4.78 ± 0.07 4.1 ± 0.10 3.77 ± 0.06 4.92 ± 0.07 4.11 ± 0.08
Data were expressed as mean ± SEM. n = 8.
* p < 0.05 compared to control.
** p < 0.01 compared to control.
*** p < 0.001 compared to control.
Table 4
Hematological parameter changes of female rats during treatment of test compounds.
Parameters Control Standard (Naproxen) Cu-Nap Co-Nap Fe-Nap Ag-Nap Zn-Nap
WBC (109/L) 4.8 ± 0.28 7.09 ± 0.43* 5.7 ± 0.37 6.21 ± 0.71 6.17 ± 0.68 5.3 ± 0.63 5.93 ± 0.47
RBC (1012/L) 5.82 ± 0.37 4.81 ± 0.28* 6.32 ± 0.16 6.69 ± 0.13 5.75 ± 0.36 5.66 ± 0.13 5.9 ± 0.18
Platelets (1011/L) 5.91 ± 0.30 6.59 ± 0.27 4.92 ± 0.25 5.04 ± 0.37 5.44 ± 0.25 5.02 ± 0.18 5.08 ± 0.22
Neutrophils (109/L) 0.87 ± 0.06 1.54 ± 0.21*** 0.98 ± 0.09 1.26 ± 0.12 1.14 ± 0.09 0.97 ± 0.09 1.02 ± 0.07
Lymphocytes (109/L) 3.87 ± 0.26 5.56 ± 0.29* 4.63 ± 0.35 4.85 ± 0.59 4.93 ± 0.57 4.25 ± 0.42 4.83 ± 0.42
Monocytes (109/L) 0.06 ± 0.008 0.13 ± 0.02* 0.1 ± 0.01 0.1 ± 0.01 0.11 ± 0.01 0.08 ± 0.01 0.08 ± 0.01
Hemoglobin (gm/dL) 10.98 ± 0.53 9.17 ± 0.44** 11.34 ± 0.21 12.09 ± 0.23 10.77 ± 0.42 10.46 ± 0.18 10.67 ± 0.29
Hematocrit (HCT) (%) 32.16 ± 1.6 26.63 ± 1.4** 33.41 ± 0.59 35.13 ± 0.58 31.27 ± 1.4 30.81 ± 0.51 31.03 ± 0.96
MCV (fL) 55.66 ± 1.5 55.54 ± 0.65 52.97 ± 0.51 52.59 ± 0.40 54.83 ± 1.2 54.49 ± 0.47 52.56 ± 0.40
MCH (pg) 19.06 ± 0.59 19.17 ± 0.26 17.99 ± 0.18 18.06 ± 0.13 18.93 ± 0.53 18.5 ± 0.14 18.1 ± 0.15
MCHC (gm/dL) 34.21 ± 0.25 34.53 ± 0.27 33.99 ± 0.11 34.36 ± 0.13 34.51 ± 0.23 33.93 ± 0.11 34.43 ± 0.13
RDW (%) 18.64 ± 2.0 18.84 ± 0.68 14.84 ± 0.57 15.07 ± 0.59 16.91 ± 1.3 15.34 ± 0.65 15.09 ± 0.41
MPV (fL) 4.19 ± 0.09 4.24 ± 0.09 4.16 ± 0.08 4.36 ± 0.13 4.11 ± 0.06 4.17 ± 0.08 4.24 ± 0.09
PDW (10 GSD) 16.36 ± 0.15 16.24 ± 0.09 16.41 ± 0.15 16.91 ± 0.32 16.44 ± 0.17 16.6 ± 0.16 16.67 ± 0.21
ESR (mm in 1st hour) 2.57 ± 0.29 2.43 ± 0.29 2.14 ± 0.14 2.14 ± 0.14 2.14 ± 0.14 2.0 ± 0.0 2.71 ± 0.28
Bleeding time (sec) 47.14 ± 3.9 47.14 ± 3.9 47.14 ± 2.1 47.14 ± 3.9 36.43 ± 3.0 38.57 ± 3.0 42.86 ± 3.9
Clotting time (min) 3.86 ± 0.09 3.86 ± 0.14 3.82 ± 0.08 4.0 ± 0.10 3.82 ± 0.07 3.96 ± 0.08 4.14 ± 0.09
Data were expressed as mean ± SEM. n = 8.
* p < 0.05 compared to control.
** p < 0.01 compared to control.
*** p < 0.001 compared to control.
Table 5
Biochemical parameter changes of male rats during treatment of test compounds.
Parameters Control Naproxen Nap-Cu Nap-Co Nap-Fe Nap-Ag Nap-Zn
Glucose (mg/dl) 123.3 ± 3.4 125.6 ± 4.3 123.5 ± 4.1 123.2 ± 4.1 124.3 ± 3.8 123.9 ± 3.9 123.8 ± 4.2
Creatinine (mg/dl) 0.85 ± 0.05 0.9 ± 0.06 0.79 ± 0.08 0.94 ± 0.08 0.78 ± 0.03 0.81 ± 0.08 0.79 ± 0.05
Protein (g/dl) 7.32 ± 0.15 7.27 ± 0.18 7.48 ± 0.11 6.77 ± 0.21 7.39 ± 0.19 7.18 ± 0.08 7.51 ± 0.21
Albumin (g/dl) 4.28 ± 0.17 4.29 ± 0.45 4.13 ± 0.16 3.5 ± 0.06 4.12 ± 0.16 4.24 ± 0.12 4.26 ± 0.15
Total cholesterol (mg/dl) 66.7 ± 4.6 68.4 ± 5.2 65.6 ± 4.3 67.7 ± 4.9 66.2 ± 4.8 65.4 ± 5.6 67.1 ± 5.8
Triglycerides (mg/dl) 86.2 ± 3.6 84.7 ± 4.5 87.1 ± 4.1 85.9 ± 3.9 87.6 ± 5.3 85.6 ± 4.9 86.6 ± 5.5
Total bilirubin (mg/dl) 0.06 ± 0.3 0.05 ± 0.3 0.07 ± 0.2 0.05 ± 0.3 0.06 ± 0.4 0.06 ± 0.7 0.05 ± 0.4
Urea (mg/dl) 14.56 ± 0.25 15.07 ± 0.55 14.61 ± 0.63 14.47 ± 0.47 15.10 ± 0.76 14.45 ± 0.65 15.01 ± 0.45
Uric acid (mg/dl) 4.19 ± 0.43 4.27 ± 0.38 3.96 ± 0.51 4.31 ± 0.44 4.11 ± 0.51 4.38 ± 0.42 4.31 ± 0.40
ALT (IU/L) 37.4 ± 3.3 38.4 ± 3.3 36.8 ± 2.7 37.8 ± 5.3 37.2 ± 3.9 36.9 ± 3.5 38.2 ± 4.1
AST (IU/L) 185.3 ± 9.8 187.3 ± 10.8 182.2 ± 10.7 187.4 ± 12.6 184.7 ± 11.4 186.3 ± 13.6 183.6 ± 12.4
Alk phos (IU/L) 52.2 ± 3.2 54.1 ± 3.5 51.5 ± 2.8 52.5 ± 3.1 52.6 ± 3.5 53.4 ± 3.4 52.8 ± 3.3
Data were expressed as mean ± SEM. n = 8.
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28th day of study. The alteration of the body weight of the exper-
imental animals was not so prominent. No significant changes
were observed.3.2.3. Hematology assessment
Animal treated with the test samples showed no significant
changes in hematological parameters. However, there were some
considerations about naproxen treated groups. Naproxen showed
Table 6
Biochemical parameter changes of female rats during treatment of test compounds.
Parameters Control Naproxen Nap-Cu Nap-Co Nap-Fe Nap-Ag Nap-Zn
Glucose (mg/dl) 121.1 ± 3.4 123.4 ± 3.2 124.1 ± 3.1 119.2 ± 4.1 122.1 ± 3.4 120.7 ± 4.4 124.8 ± 5.5
Creatinine (mg/dl) 0.83 ± 0.04 0.7 ± 0.05 0.77 ± 0.06 0.74 ± 0.04 0.78 ± 0.03 0.77 ± 0.08 0.82 ± 0.05
Protein (g/dl) 6.51 ± 0.21 6.27 ± 0.21 6.48 ± 0.31 6.27 ± 0.27 6.39 ± 0.12 6.58 ± 0.1 6.51 ± 0.29
Albumin (g/dl) 3.82 ± 0.25 3.92 ± 0.53 3.86 ± 0.34 3.72 ± 0.16 3.78 ± 0.23 3.84 ± 0.17 3.62 ± 0.19
Total cholesterol (mg/dl) 64.7 ± 3.6 66.4 ± 3.8 63.7 ± 2.9 65.8 ± 3.4 64.3 ± 3.6 63.9 ± 2.7 65.2 ± 3.2
Triglycerides (mg/dl) 84.4 ± 2.6 82.8 ± 3.2 85.3 ± 3.4 82.2 ± 4.1 85.5 ± 3.7 83.7 ± 3.4 81.9 ± 4.3
Total bilirubin (mg/dl) 0.05 ± 0.2 0.04 ± 0.4 0.06 ± 0.4 0.04 ± 0.3 0.05 ± 0.5 0.05 ± 0.3 0.04 ± 0.3
Urea (mg/dl) 12.56 ± 0.25 13.07 ± 0.43 12.61 ± 0.51 12.47 ± 0.42 13.10 ± 0.45 12.45 ± 0.31 13.01 ± 0.32
Uric acid (mg/dl) 3.49 ± 0.31 3.27 ± 0.47 3.56 ± 0.58 3.61 ± 0.52 4.0 ± 0.78 3.71 ± 0.61 3.93 ± 0.67
ALT (IU/L) 35.4 ± 2.9 36.4 ± 4.1 34.8 ± 3.7 35.8 ± 3.8 35.2 ± 4.9 34.9 ± 2.6 36.2 ± 3.9
AST (IU/L) 182.3 ± 10.3 184.3 ± 10.1 180.2 ± 9.7 185.4 ± 11.1 181.7 ± 9.9 183.3 ± 10.2 181.6 ± 11.1
Alk phos (IU/L) 50.5 ± 2.1 52.3 ± 3.4 49.8 ± 2.3 50.3 ± 3.7 50.6 ± 2.9 51.8 ± 2.2 51.9 ± 3.8
Data were expressed as mean ± SEM. n = 8.
Table 7
GI effects of different groups of rats under the experimental period.
Group Observed parameters for male rat
Number of ulcers (Mean ± SEM) Average Ulcer score (Mean ± SEM) Ulcer index (Mean ± SEM) Inhibition of ulceration (%)
Control – – – –
Naproxen 2.1 ± 0.26 1.3 ± 0.09 13.4 ± 0.29 –
N-Cu 0.9 ± 0.14*** 0.8 ± 0.18 10.2 ± 0.30*** 23.88
N-Co 1.1 ± 0.14* 0.8 ± 0.10 11.9 ± 0.20* 11.19
N-Fe 1.1 ± 0.14* 0.8 ± 0.10 11.9 ± 0.20* 11.19
N-Ag 1.0 ± 0.31** 1.0 ± 0.31 9.1 ± 0.62*** 32.09
N-Zn 1.1 ± 0.26* 0.9 ± 0.25 10.6 ± 0.51*** 20.89
For female rat
Control – – – –
Naproxen 1.9 ± 0.21 1.1 ± 0.08 12.3 ± 0.27 _
N-Cu 0.8 ± 0.15*** 0.7 ± 0.17 10.8 ± 0.31*** 22.71
N-Co 1.3 ± 0.13* 0.9 ± 0.10 12.1 ± 0.19* 11.94
N-Fe 1.2 ± 0.13* 0.9 ± 0.14 12.4 ± 0.48* 12.79
N-Ag 1.4 ± 0.14* 1.1 ± 0.10 12.3 ± 0.20* 12.01
N-Zn 0.9 ± 0.34*** 1.3 ± 0.41 9.8 ± 0.72*** 32.45
Data were expressed as mean ± SEM. n = 8.
* p < 0.05 compared to standard.
** p < 0.01 compared to standard.
*** p < 0.001 compared to standard.
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and increasing the number of white blood cells count, neutrophils,
lymphocytes andmonocytes (Tables 3 and 4). As the values are sta-
tistically significant, this was a clear indication of inflammation
and might create pathological condition in near future. Other
parameters were found in normal compared to control. However,
in case of metal complexes there were no alterations in the value
of those parameters in both male and female rats. This suggested
that those complexes were comparatively safer drugs than parent
naproxen.
3.2.4. Biochemical assessment
All the biochemical parameters studied were found to be com-
parable with control group. In both male and female rats groups,
no significant changes were seen in any parameters (Tables 5
and 6). However, the blood glucose and cholesterol level seemed
to be higher and triglyceride was found lower for naproxen treated
groups.
3.2.5. GI side effects assessment
GI side effects (ulceration/bleeding) can be assessed by measur-
ing hematocrit (index of anemia caused by GI bleeding), and
inspecting the GI tract for lesions, perforations and adhesions
(Table 7). The stomach and small intestine were then blindly eval-
uated for hemorrhagic damage. This involved measuring the
lengths, in mm, of all hemorrhagic lesions. Separate gastric andintestinal damage scores were then calculated by summing the
lengths of all lesions for each rat.214. Discussion
In our previous paper,22 we showed that naproxen metal com-
plexes had better pharmacological properties than naproxen in
mice. That’s why we thought there might be possibilities that they
could have any toxicity profiles. In the present investigation, there
were no significant alterations in histopathological studies and
physical parameters though some signs of abnormalities had been
found but hematological and hormonal data did not suggest any
inflammatory or toxicological activity. However, we observed that
naproxen showed more side effects than metal complexes that
indicated that carboxylic group (ACOOH) of naproxen may be
responsible for showing those most of the side effects. Based on
this result we strongly believe that ACOOH group of naproxen pre-
dominantly responsible for showing side effects in various com-
partments of the body. Hence metal complexes lack the ACOOH
group because of complication with metals they did not show
any considerable side effects than naproxen. No any major changes
in behavior or tremors/convulsions or body weight were seen dur-
ing the study period. Hematological reports indicated that there
was increase in the number of white blood cell count, neutrophils,
lymphocytes and monocytes and simultaneously decrease in
350 M.S. Hasan et al. / Alexandria Journal of Medicine 53 (2017) 345–350hemoglobin, hematocrit that clearly stated that the inflammation
was on progress for naproxen. However, all of these parameters
were found normal in metal complexes of naproxen and also a
clear indication of safety compared to parent naproxen. Biochemi-
cal parameters related to kidney function were found normal for all
the samples. However, glucose level of the naproxen treated ani-
mals showed higher value than control and other samples. In over-
all, we tried to figure out a detailed scenario of the toxicity
profiling of naproxen metal complexes. In general it can be said
that they are comparatively safer than naproxen.
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